literature

HIV mutation literature information.

Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.

PMID: 27231099 2016 Journal of the International AIDS Society

Table: K219E

From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.

PMID: 28010730 2016 BMC research notes

Table: K219E

Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.

PMID: 26512902 2015 PloS one

Discussion: Despite the extensive use of thymidine analogues like AZT or D4T in Ethiopia and unlike previous similar studies, TAMs characterized by the mutations M41L, L210W, T215Y (TAM-path 1) and D67N, K70R, T215F, K219Q/E (TAM-path 2) were lacking in the current study indicating a recent period of virological failure.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

PMID: 26717411 2015 PloS one

Result: The TAMs M41L, D67N/E/G and K219Q/E/N/R and the T215 revertant mutations (T215C/D/E/S/I/V) were the most common non-major transmitted NRTI DRMs.

HIV-1 subtype characteristics of infected persons living in southwestern Greece.

PMID: 26715861 2015 HIV/AIDS (Auckland, N.Z.)

Result: The 22 cases experiencing virologic failure presented with the following DRMs: M46I, F53LY, I54LTV, G73ST, L76V, V82AT, I84V, I185V, N88D, and L90M for PIs; L100I, K103NS, V179F Y181C, G190AS, V106A, K103N, and P225H for NNRTIs; and

Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years.

PMID: 25777786 2015 Journal of medical virology

Abstract: The most prevalent TDR mutations were: T215 revertants (1.5%), K219QENR (1.2%), for NRTIs; K103N (1.9%), for NNRTIs; L90M (0.3%), for PIs.

AZT resistance alters enzymatic properties and creates an ATP-binding site in SFVmac reverse transcriptase.

PMID: 25808094 2015 Retrovirology

Introduction: Amino acid sequence alignments of the polymerase domains of SFVmac and HIV-1 revealed that the SFVmac AZT resistance mutations do not correspond to the ones obtained with highly AZT-resistant HIV-1 RT (M41L, D67N, K70R, T215Y/F and K219Q/E).

Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.

PMID: 25754408 2015 Journal of medical virology

Result: A wide range of mutations conferring multi-NRTI resistance were also observed, including M41L (n = 7, 10%), A62V (n = 15, 22%), D67N (n = 10, 15%), K70R (n = 10, 15%), V75I (n = 2, 3%), F77L (n = 1, 1%), Y115F (n = 6, 9%), F116Y (n = 1, 1%), Q151M (n = 1, 1%), L210W (n = 3, 4%), T215Y/F (n = 7, 10%) and (n = 5, 7%), and K219Q/E (n = 4, 6%) and (n = 7, 10%).

Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.

PMID: 25765644 2015 Nucleic acids research

Introduction: L210W and K219Q/E that potentiate ZDV resistance in the context of other TAMs.

Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals.

PMID: 26355575 2015 AIDS (London, England)

Discussion: We show here that D30N, N88D/S and L90 M also have high transmissibility and that other SDRMs have higher (M41L, T215Rev and K219E/N/Q/R for NRTIs and K101E/P for the NNRTIs) or lower transmissibility (K70E/R, L74I/V, and T215Y/F for NRTIs; Y181C/I/V for NNRTIs and I84 V and I54A/L/M/S/T/V for protease inhibit

Browser Board

Co-occurred Entities

Filtrator